Company Overview
Zura Bio Limited operates as a clinical-stage biotechnology firm dedicated to developing therapeutic medicines for immune and inflammatory disorders within the United States. The company focuses its research and development efforts on Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered through the fusion of ixekizumab, targeting specific biological pathways to modulate immune responses. This entity functions within the broader Healthcare sector, specifically the Biotechnology industry, which is characterized by high capital expenditure requirements and significant regulatory scrutiny before products reach commercialization. As of the latest available data, Zura Bio Limited holds a market capitalization of $537.97M and employs approximately 30 individuals to execute its strategic roadmap. The current market valuation indicates that the company is valued as a mid-cap entity, yet the absence of reported annual revenue figures suggests the business remains in a pre-revenue or early commercialization phase where value is derived primarily from intellectual property potential rather than current sales performance.
Financial Health
The company reports a net income of $-62,520,000 and an EBITDA of $-72,528,000 for the trailing twelve months, while revenue data is not disclosed in the current financial filings. The substantial gap between the reported net income loss and the EBITDA loss reveals a significant cost structure driven by operating expenses, including research and development, general administration, and stock-based compensation, which are typical for clinical-stage biotechnology firms. Zura Bio Limited generated a free cash flow of $-28,158,376, a figure that underscores the company's current burn rate and its reliance on external capital sources such as equity financing or strategic partnerships to fund ongoing operations. All three reported margin metrics—gross margin, operating margin, and profit margin—are listed as 0.0%, which reflects the standard accounting presentation for entities that have not yet achieved commercial scale or have recorded costs that exceed their recognized revenue in a manner that nullifies standard margin calculations. On the balance sheet, the company holds $139.02M in cash and cash equivalents while debt data is not available, resulting in a debt-to-equity ratio that is not applicable due to the lack of debt figures. The current ratio stands at 5.58, a level that indicates strong short-term liquidity and a robust ability to meet its current liabilities with its liquid assets. Furthermore, the return on equity is -45.0% and the return on assets is -27.2%, metrics that highlight the dilution of shareholder value and asset efficiency in the context of a company that is still incurring losses to advance its clinical pipeline.
Valuation Assessment
The valuation of Zura Bio Limited is represented by a forward P/E ratio of -56.70, while the trailing P/E ratio is not applicable, a disparity that implies the market is pricing the stock based on future earnings expectations that have not yet been realized in the past. The price-to-book ratio is recorded at 3.41, suggesting that the market is currently valuing the company at a premium of 3.41 times its book value, which often occurs in biotechnology sectors where intangible assets like patents are significant components of the company's worth. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not applicable or listed as negative values, reflecting the speculative nature of investing in a company with no current sales and negative earnings. The stock has exhibited significant volatility over the last year, with a 52-week high of $7.44 and a 52-week low of $0.97. Given the wide range between these extremes, the current trading price is situated well below the recent high, indicating a correction from peak market sentiment regarding the company's asset potential. The beta value is 0.18, which suggests that the stock price is less volatile than the broader market and tends to move with less intensity relative to general market fluctuations.
Growth & Income
The company reports no available data for revenue growth year-over-year or earnings growth year-over-year, which is consistent with the financial profile of a clinical-stage entity that has not yet transitioned to a revenue-generating phase of maturity. Consequently, the earnings growth rate cannot be compared to revenue growth as both metrics are absent, but the financial trajectory points toward a period of investment rather than expansion of top-line sales. Zura Bio Limited does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available resources and any generated cash flow back into its research and development operations rather than distributing income to shareholders. This non-dividend strategy aligns with the capital-intensive nature of the biotechnology industry, where preserving cash is essential for advancing clinical trials and securing regulatory approvals. The overall growth and income profile is characterized by high operational risk and a lack of current cash returns, relying entirely on the future successful commercialization of its drug candidates to generate positive cash flows and shareholder value.